FDA
-
-
-
-
-
-
-
Press release: Sanofi successfully prices USD 3 billion of bond issue
-
-
-
-
-
-
-
Sanofi to acquire Blueprint Medicines, $129 per share
-
-
-
-
-
-
-
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
-
-
-
-
-
-
-
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
-
-
-
-
-
-
-
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
-
-
-
-
-
-
-
Sanofi ships U.S. influenza vaccines for the 2024/25 season
-
-
-
-
-
-
-
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

